Skip to main content
  • Renal Denervation: FDA Panel, Industry Mostly on the Same Page

    Consensus largely greenlights development plans

    GAITHERSBURG, Md. -- Industry seems to have learned from early mistakes with renal denervation, as development for device-based hypertension treatment appears to be headed in line with expectations of an FDA advisory panel.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details